撒哈拉以南非洲齐多夫定一线ART持续病毒学失败后HIV-1胸苷类似物突变的快速积累及其表型影响
该回顾性分析基于NORA研究第48周至96周持续病毒学失败的36对基因型样本,评估含齐多夫定一线ART方案下胸苷类似物突变(TAMs)的积累及表型耐药变化。结果显示第96周时奈韦拉平组和 abacavir 组分别有50%和73%的患者存在≥3个TAMs,齐多夫定敏感性从第48周至第96周显著下降(几何平均倍数变化1.3 vs 3.4,P=0.01),替诺福韦敏感性仅小幅降低(0.7 vs 1.0,P=0.18)。结论认为持续病毒学失败与耐药快速增加相关,有效病毒载量监测可减轻该问题。
要点
- 含齐多夫定一线ART持续失败时TAMs快速积累,第96周半数以上患者出现≥3个TAMs。
- 齐多夫定表型敏感性在48至96周间显著下降(FC 1.3→3.4,P=0.01)。
- 替诺福韦敏感性仅小幅降低且未达统计学显著(FC 0.7→1.0,P=0.18)。
核心结论
- 含齐多夫定一线ART持续病毒学失败与耐药快速增加相关,有效病毒载量监测可减轻该问题。
研究设计与样本
- 对NORA研究第48周至96周持续病毒学失败个体进行回顾性分析,纳入36对基因型样本。
- 14例接受齐多夫定/拉米夫定/奈韦拉平,22例接受齐多夫定/拉米夫定/abacavir。
- 表型耐药采用Antivirogram assay(v. 2.5.01, Janssen Diagnostics)评估。
主要发现
- 第96周时≥3个TAMs在奈韦拉平组占50%,在abacavir组占73%。
- 第48至96周平均(SE)累积TAMs数:奈韦拉平组1.50(0.37),abacavir组1.82(0.26)。
- 齐多夫定敏感性几何平均倍数变化从第48周1.3降至第96周3.4(P=0.01)。
- 替诺福韦敏感性几何平均倍数变化从第48周0.7升至第96周1.0(P=0.18)。
临床怎么用
- 在含齐多夫定一线ART持续病毒学失败时,应警惕TAMs快速积累及齐多夫定耐药。
- 有效病毒载量监测有助于及早发现失败并减少多药耐药HIV-1的流行。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lack of viral load monitoring of ART is known to be associated with slower switch from a failing regimen and thereby higher prevalence of MDR HIV-1. Many countries have continued to use thymidine analogue drugs despite recommendations to use tenofovir in combination with a cytosine analogue and NNRTI as first-line ART. The effect of accumulated thymidine analogue mutations (TAMs) on phenotypic resistance over time has been poorly characterized in the African setting. PATIENTS AND METHODS: A retrospective analysis of individuals with ongoing viral failure between weeks 48 and 96 in the NORA (Nevirapine OR Abacavir) study was conducted. We analysed 36 genotype pairs from weeks 48 and 96 of first-line ART (14 treated with zidovudine/lamivudine/nevirapine and 22 treated with zidovudine/lamivudine/abacavir). Phenotypic drug resistance was assessed using the Antivirogram assay (v. 2.5.01, Janssen Diagnostics). RESULTS: At 96 weeks, extensive TAMs (≥3 mutations) were present in 50% and 73% of nevirapine- and abacavir-treated patients, respectively. The mean (SE) number of TAMs accumulating between week 48 and week 96 was 1.50 (0.37) in nevirapine-treated participants and 1.82 (0.26) in abacavir-treated participants. Overall, zidovudine susceptibility of viruses was reduced between week 48 [geometric mean fold change (FC) 1.3] and week 96 (3.4, P = 0.01). There was a small reduction in tenofovir susceptibility (FC 0.7 and 1.0, respectively, P = 0.18). CONCLUSIONS: Ongoing viral failure with zidovudine-containing first-line ART is associated with rapidly increasing drug resistance that could be mitigated with effective viral load monitoring.
引用
- Goodall RL, Dunn DT, Nkurunziza P, et al. Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa. J Antimicrob Chemother. 2017. PMID: 28160504. doi:10.1093/jac/dkw583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。